NEW DELHI: Drug Controller General of India V.G. Somani has approved the use of Gilead Sciences Inc’s novel drug remdesivir to treat covid-19 patients, Lav Aggarwal, joint secretary in the health ministry, said on Tuesday. “The DCGI gave an emergency use permission for remdesivir...
and this was based on evidence that was provided by the company to support its use against covid-19," Aggawal said at a press conference.
Aggarwal said further details on the protocols for use of the intravenous drug will be provided by the government in due course.
In India, Gilead has given voluntary licence for production of remdesivir to Cipla, Jubilant Life Sciences, Hetero Drugs and Mylan under a royalty-free arrangement till an alternative drug is found